The Role of FGFR3 in the Progression of Bladder Cancer
Cancers · 06.11.2025 · 17 (21) · 3588
DOI: 10.3390/cancers17213588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 06.11.2025. Verfasst von Sahoko Ninomiya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama 232-0024, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Bladder cancer is associated with a high recurrence rate, and outcomes for muscle-invasive and metastatic disease remain poor. New targeted therapies, such as the FGFR inhibitor erdafitinib, have been introduced, but the progression from non-muscle-invasive to muscle-invasive disease remains a major clinical challenge.
Methods
In this study, we performed immunohistochemical staining for FGFR1-FGFR4 on surgical specimens from 192 cases of urothelial carcinoma. We also conducted various functional assays on human bladder cancer cell lines to assess protein/gene expression, cell proliferation, migration, invasion, and colony formation.
Results
FGFR2 and FGFR3 expressions were found to be significantly down-regulated in high-grade (0.014) and muscle-invasive (0.002) tumors, respectively. Functionally, the FGFR inhibitor erdafitinib suppressed cell proliferation and migration, and FGFR3 silencing also markedly reduced proliferation, migration, invasion, and colony formation in cancer cell lines.
Conclusions
The down-regulation of FGFR3 in muscle-invasive bladder cancer, coupled with the inhibitory effect of its inactivation on cell growth, suggests a significant role for FGFR3 in bladder cancer progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
- Department of Urology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
- Departments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.
ORCID-Profile: Hisashi Hasumi, Akihito Hashizume, Kazuhide Makiyama, Hiroshi Miyamoto
Zitieren
APA
Ninomiya, S., Ishiguro, Y., Hasumi, H., Jikuya, R., Hashizume, A., Yamazaki, M., Teranishi, J. I., Makiyama, K., Uemura, H., Miyamoto, H., & Kawahara, T. (2025). The Role of FGFR3 in the Progression of Bladder Cancer. Cancers, 17(21), 3588. https://doi.org/10.3390/cancers17213588
Vancouver
Ninomiya S, Ishiguro Y, Hasumi H, Jikuya R, Hashizume A, Yamazaki M, et al. The Role of FGFR3 in the Progression of Bladder Cancer. Cancers. 2025;17(21):3588. doi:10.3390/cancers17213588
BibTeX
@article{Ninomiya2025,
author = {Ninomiya, Sahoko and Ishiguro, Yukari and Hasumi, Hisashi and Jikuya, Ryosuke and Hashizume, Akihito and Yamazaki, Masanobu and Teranishi, Jun-Ichi and Makiyama, Kazuhide and Uemura, Hiroji and Miyamoto, Hiroshi and Kawahara, Takashi},
title = {The Role of FGFR3 in the Progression of Bladder Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {21},
pages = {3588},
doi = {10.3390/cancers17213588}
}
EUVIMED